People with type 2 diabetes who stopped GLP-1 drugs had higher rates of heart attack, stroke or death than those who continued treatment, an observational study found. According to ABC Australia, Using records collected between 2004 and 2024, the study followed over 80,000 Italians with type 2 diabetes but no established cardiovascular disease.

According to ABC Australia, About four in 100 people who stopped treatment experienced a heart attack, stroke or died from any cause, compared with about two in 100 who continued. According to Euronews, Because the research was observational, it could not determine whether stopping the drugs caused the increased risk or whether discontinuation marked poorer health.

According to Euronews, Among participants who stopped treatment, the risk of adverse outcomes was higher for those with obesity than for those without obesity. The analysis drew on electronic health records kept across over 300 diabetes clinics and held in the Italian Association of Clinical Diabetologists database.

According to Euronews, Participants who continued GLP-1 treatment used it for nearly three years on average, while those who stopped had taken it for just over one year. According to ABC Australia, the study included people who had started GLP-1 treatment, but did not establish whether stopping carried greater risk than never taking the drugs.

According to ABC Australia, Lead author Antonio Ceriello theorised that GLP-1 drugs might offer direct cardiovascular protection, but the study did not establish that mechanism. According to Euronews, Semaglutide made up only a small share of treatment in the study, and the researchers did not include tirzepatide.

According to Euronews, Tirzepatide was excluded because it entered the Italian market after the study period, which concluded in 2024. Most participants received earlier-generation GLP-1 medicines, limiting how broadly the findings apply to newer treatments.

According to ABC Australia, Professor Chow noted that the discontinuation group had a very high rate of death from any cause and may have been sicker than those who continued. Associate Professor Brendon Neuen said patients may stop treatment for an appropriate medical reason and that such patients are typically sicker.

According to ABC Australia, Natalie Raffoul, head of clinical strategy at The Heart Foundation, called the findings interesting and said more research was needed to understand the consequences of stopping. Neuen said people with a chronic condition helped by GLP-1 treatment should talk with a health professional before stopping.

GLP-1 medicines mimic glucagon-like peptide-1, helping regulate blood sugar and weight in people with type 2 diabetes. According to ABC Australia, Professor Chow said people taking GLP-1 drugs for extended periods need monitoring, and more information is needed about long-term effects and side effects.